Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Paraspeckle component 1 (PSPC1) is a multifunctional RNA-binding protein and the first-discovered core structural protein of paraspeckles, which are subnuclear, membrane-less organelles found adjacent to splicing speckles in transcriptionally active cells[1][2][3][4]. PSPC1 contains two N-terminal RNA recognition motifs (RRM1, RRM2), a NONA/paraspeckle domain (NOPS), and a C-terminal coiled-coil domain essential for paraspeckle assembly and function[1][4]. PSPC1 participates in the regulation of gene expression, DNA damage repair, mRNA modification, cell fate determination, differentiation, and immune responses; it is overexpressed or dysregulated in various cancers, where it facilitates metastasis and therapy resistance, making it a candidate biomarker and therapeutic target[1][2][3][4].
For drugs targeting pathways modulated by PSPC1: Inhibition of PSPC1 enhances DNA damage and causes mitotic catastrophe in cancer cells treated with PARP inhibitors. PSPC1 suppression may reverse endocrine therapy resistance in hormone-positive cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Paraspeckle component 1 (PSPC1).